2. Immunology/Inflammation
  3. CD19 CD28
  4. RG-6333

RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003).

For research use only. We do not sell to patients.

RG-6333 Chemical Structure

RG-6333 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

RG-6333 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003)[1][2].

In Vitro

RG-6333 (RO 7443904) has a lower affinity for CD28 in CHO cells (Kd: 36 nM), binding weakly but sufficient to provide a co-stimulatory signal[1].
RG-6333 is inactive as a single agent in human peripheral blood mononuclear cells (PBMC) and activates T cells only upon engagement of the T cell receptor (TCR)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RG-6333 Related Antibodies
In Vivo

RG-6333 (1,10 mg/kg, i.v. one dose) activates T cells only in the presence of T cell receptor (TCR) signaling in humanized NSG mice and does not induce a cytokine storm[1][2].
RG-6333 (1 mg/kg, i.v. one dose) significantly inhibits tumor growth in humanized NSG mice bearing subcutaneous NALM-6 lymphoma in combination with Glofitamab (HY-P99024) (0.15 mg/kg), and increases tumor-infiltrating CD8+ T cells[1].
RG-6333 (1 mg/kg, i.v. one dose) combines with Glofitamab (0.15 mg/kg) in an aggressive in vivo lymphoma (DLBCL WSU-DLCL2-Fluc) humanized mice model results in complete tumor regression, with an initial transient weight loss due to T cell activation, but subsequent recovery[1][2].
RG-6333 (1 mg/kg, i.v. one dose) combines with glofitamab (0.15 mg/kg) in a humanized NSG mice model bearing subcutaneous OCI-Ly18 tumors increases pro-inflammatory T cell signatures in tumors and promotes transendothelial migration, and triple combination with CD19–4-1BBL deepens and prolongs anti-tumor responses in vivo[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Humanized NSG mice bearing orthotopic WSU-DLCL2-Fluc tumors[1]
Dosage: 1 mg/kg
Administration: i.v. three times combined injection
Result: Combined with Glofitamab (0.15 mg/kg) achieved complete tumor regression, with initial weight loss in mice, which is related to the mode of action of TCB and its induced cytokine release.
Combined with Glofitamab (0.15 mg/kg) led to subsequent recovery of mice without additional weight loss suggestive of tumor progression, indicated potent antitumor activity.
Animal Model: OCI-Ly18 tumor-bearing humanized NSG mice[1]
Dosage: 1 mg/kg
Administration: i.v. three times combined injection
Result: Combined with Glofitamab (1 mg/kg) increased intratumoral CD8+ and CD4+ T-cell counts.
Combined with Glofitamab (1 mg/kg) led to a marked increase in IFNγ pathway genes, followed by significantly increased cytotoxic T-cell and decreased B-cell signatures.
Combined with Glofitamab (1 mg/kg) and CD19-4-1BBL (1 mg/kg) prolonged the anti-tumor response in vivo and achieving long-term tumor control.
SMILES

[RG-6333]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

RG-6333 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

RG-6333RO7443904RG6333RG 6333RO 7443904RO-7443904CD19CD28immunotherapyhumanized NSG micelymphomaglofitamabInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
RG-6333
Cat. No.:
HY-P991176
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.